Journal Article

Engineering cancer resistance in mice

Peter Klatt and Manuel Serrano

in Carcinogenesis

Volume 24, issue 5, pages 817-826
Published in print May 2003 | ISSN: 0143-3334
Published online May 2003 | e-ISSN: 1460-2180 | DOI: http://dx.doi.org/10.1093/carcin/bgg057
Engineering cancer resistance in mice

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics

GO

Show Summary Details

Preview

Research on cancer has benefited enormously from the genetic manipulation of mice. Until recently, most of the emphasis has been put on tailoring genetic alterations to accelerate tumorigenesis or to recapitulate particular aspects of the tumorigenic process. The goal of engineering mice with an increased resistance to cancer is a novel aspect that is of importance to understand cancer susceptibility and to validate therapeutic and chemopreventive strategies. Here, we review the different mouse models described to date that manifest a ‘cancer resistance’ phenotype, with a particular emphasis on the molecular basis of the resistance and on the associated phenotypes that may have a negative impact on health.

Keywords: AP-1, activator protein-1; BMP, bone morphogenetic proteins; COX, cyclooxygenase isozyme; DNMTs, DNA methyl-transferase isozymes; IGF-1, insulin-like growth factor-1; Min, multiple intestinal neoplasia; Mom-1, modifier of Min-1; NO, nitric oxide; NOS-2, NO synthase; PLA2 s, phospholipase A2 enzymes; TGF-β, transforming growth factor-β; TNF, tumour necrosis factor.

Journal Article.  8496 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.